



Tata India Pharma & Healthcare Fund


(An Open-Ended Equity Scheme investing in Pharma & Healthcare Services Sector)

June 2020

This product is suitable for investors who are seeking*:

- Long Term Capital Appreciation.
- Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India.

***Investors should consult their financial advisors if in doubt about whether the product is suitable for them**



Investors understand that their principal will be at High risk

ADVANTAGE INDIA – PHARMA AND HEALTHCARE SERVICES



Cost Efficiency

1. Low cost of production and R&D boosts efficiency of Indian pharma companies.
2. India's cost of production is approximately 33 per cent lower than that of the US.
3. India's ability to manufacture high quality, low priced medicines, presents a huge business opportunity for the domestic industry

Economic Drivers

1. Economic prosperity to improve drug affordability
2. Increasing penetration of health insurance
3. With increasing penetration of chemists, especially in rural India, OTC drugs will be readily available

Diversified Portfolio

1. Accounts for over 10 per cent of the global pharmaceutical production
2. Over 60,000 generic brands across 60 therapeutic categories. Manufactures more than 500 different APIs
3. More than half of all 345 drug master filings (DMFs) in the USA in Q4 2016 and Q1 2017 were from India


Policy Support

1. Government unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacturing
2. Reduced approval time for new facilities to boost investments
3. In this sector, 100 per cent FDI is allowed under automatic route

INDIAN PHARMA SECTOR REVENUES TRENDING NORTH



Revenue of Indian pharmaceutical sector (US\$ billion)




By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and 6th largest market globally in absolute size.

PHARMA EXPORT TO CONTINUE WITNESSING HIGH GROWTH



Export data of Indian Pharma Sector (US\$ billion)



India is the world's largest provider of generic medicines; the country's generic drugs account for 20 per cent of global generic drug exports (in terms of volumes)

Source: Department of Commerce India, Department of Pharmaceuticals, India Business News, BMI

API IS THE LARGEST SEGMENT OF THE INDIAN PHARMACEUTICALS INDUSTRY



Active Pharmaceutical Ingredients (APIs)

1. India has become the third largest global generic API merchant market by 2016, with a 7.2 per cent market share.
2. The Indian pharmaceutical industry accounts for the 2nd largest number of Abbreviated New Drug Applications (ANDAs), is the world's leader in Drug Master Files (DMFs) applications with the US

Contract Research and Manufacturing Services (CRAMS)

1. Fragmented market with more than 1,000 players.
2. CRAMS industry is estimated to reach US\$ 18 billion in 2018 and expected to witness a strong growth at a CAGR of 18-20 per cent between 2013-2018

Pharmaceutical Industry

Formulations

1. Largest exporter of formulations in terms of volume, with 14 per cent market share and 12th in terms of export value.
2. Domestic market size currently valued at US\$ 11.2 billion
3. Double-digit growth expected over the next five years

Biosimilars

1. The government plans to allocate US\$ 70 million for local players to develop Biosimilars
2. The domestic market is expected to reach US\$ 40 billion by 2030

FUND FACTS



Benchmark

Nifty Pharma TRI (WEF From 1st February 2018)

Performance History

Since December 28th , 2015

Portfolio Orientation

Investment in 80% of its assets in equity/equity related instruments of the companies in the Pharma & Healthcare services sector in India



Fund Manager

Meeta Shetty – (Fund Manager) & Rahul Singh - (Co Fund Manager)

Exit Load

0.25% of NAV if redeemed on or before expiry of 3 months from the date of allotment.

PORTFOLIO HIGHLIGHTS – TATA INDIA PHARMA & HEALTHCARE FUND




Data as of 30th June 2020

Portfolio Composition as per our Internal Calculation. For Market Cap : Please refer note no 9 under Disclaimer.



TATA INDIA PHARMA & HEALTH CARE FUND – Current Value of Initial Investment of RS. 10,000/-



Performance of the Scheme :

Tata India Pharma And Healthcare Fund			Nifty Pharma TRI*		Nifty 50 TRI#	
Period	Return %	Rs.	Return %	Rs.	Return %	Rs.
1 Year	28.66%	12,893	25.07%	12,530	-11.51%	8,840
3 Year	8.63%	12,822	2.10%	10,642	3.95%	11,233
5 Year	NA	NA	NA	NA	NA	NA
Since Inception	2.49%	11,171	-3.41%	8,554	7.36%	13,773
Inception Date	28-Dec-15		Managing Since			20-Apr-20

Data as of 30th June 2020

Fund Managers : Meeta Shetty - Fund Manager (Managing Since 20th April 2020) & Rahul Singh - Co Fund Manager (Managing Since 20th April 2020)

Past performance may or may not be sustained in future

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully

Performance data of Other Schemes Managed by Meeta Shetty



Tata Digital India Fund			S&P BSE IT TRI*		S&P BSE Sensex TRI#	
Period	Return %	Rs.	Return %	Rs.	Return %	Rs.
1 Year	-6.30%	9,365	-2.85%	9,713	-10.40%	8,952
3 Year	14.48%	15,009	17.06%	16,049	5.31%	11,681
5 Year	NA	NA	NA	NA	NA	NA
Since Inception	8.08%	14,196	8.93%	14,707	8.06%	14,182
Inception Date	28-Dec-15		Managing Since		20-Apr-20	

Tata Large & Mid Cap Fund			Nifty Large Midcap 250 TRI*		S&P BSE Sensex TRI#	
Period	Return %	Rs.	Return %	Rs.	Return %	Rs.
1 Year	-9.55%	9,037	-10.38%	8,954	-10.40%	8,952
3 Year	1.86%	10,568	1.26%	10,383	5.31%	11,681
5 Year	5.30%	12,951	6.33%	13,597	5.98%	13,372
Since Inception	11.39%	191,145	NA	NA	11.21%	182,893
Inception Date	25-Feb-93		Managing Since		01-Nov-19	

Data as of 30th June 2020

Past performance may or may not be sustained in future

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully

Performance data of Other Schemes Managed by Rahul Singh

Tata Balanced Advantage Fund			CRISIL Hybrid 35+65 - Aggressive Index*		S&P BSE Sensex TRI [#]	
Period	Return %	Rs.	Return %	Rs.	Return %	Rs.
1 Year	0.75%	10,076	-1.22%	9,877	-10.40%	8,952
3 Year	NA	NA	NA	NA	NA	NA
5 Year	NA	NA	NA	NA	NA	NA
Since Inception	4.43%	10,635	4.81%	10,691	-0.37%	9,947
Inception Date	28-Jan-19		Managing Since		09-Jan-19	

Tata Digital India Fund			S&P BSE IT TRI*		S&P BSE Sensex TRI [#]	
Period	Return %	Rs.	Return %	Rs.	Return %	Rs.
1 Year	-6.30%	9,365	-2.85%	9,713	-10.40%	8,952
3 Year	14.48%	15,009	17.06%	16,049	5.31%	11,681
5 Year	NA	NA	NA	NA	NA	NA
Since Inception	8.08%	14,196	8.93%	14,707	8.06%	14,182
Inception Date	28-Dec-15		Managing Since		20-Apr-20	

Tata Resources & Energy Fund			Nifty Commodities TRI*		Nifty 50 TRI [#]	
Period	Return %	Rs.	Return %	Rs.	Return %	Rs.
1 Year	3.03%	10,306	-19.78%	8,008	-11.51%	8,840
3 Year	1.83%	10,559	-3.65%	8,942	3.95%	11,233
5 Year	NA	NA	NA	NA	NA	NA
Since Inception	8.92%	14,699	6.29%	13,165	7.36%	13,773
Inception Date	28-Dec-15		Managing Since		20-Apr-20	

Data as of 30th June 2020

Past performance may or may not be sustained in future

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully

Performance data of Other Schemes Managed by Rahul Singh



Tata Young Citizens Fund			S&P BSE 200 TRI*		S&P BSE Sensex TRI#	
Period	Return %	Rs.	Return %	Rs.	Return %	Rs.
1 Year	-5.81%	9,414	-10.41%	8,951	-10.40%	8,952
3 Year	-1.07%	9,683	2.89%	10,892	5.31%	11,681
5 Year	2.78%	11,473	5.82%	13,274	5.98%	13,372
Since Inception	11.38%	143,569	11.42%	144,995	11.35%	142,934
Inception Date	14-Oct-95		Managing Since			20-Apr-20

Data as of 30th June 2020

Past performance may or may not be sustained in future

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully



Disclaimer:

- 1) Scheme returns in terms of CAGR are provided for past 1 year, 3 years, 5 years and since inception.
- 2) Point-to-point returns on a standard investment of Rs. 10,000/- are in addition to CAGR for the schemes.
- 3) Different plans shall have a different expense structure. The performance details provided herein are of regular plan Growth Option except for Tata Equity Savings Fund where performance details given is for regular plan for dividend option.
- 4) NA stands for schemes in existence for more than 1 year but less than 3 years or 5 years, or instances where benchmark data for corresponding period not available.
- 5) Period for which schemes performance has been provided is computed basis last day of the month - end preceding the date of advertisement.
- 6) Past performance may or may not be sustained in future. For computation of since inception returns the allotment NAV has been taken as Rs. 10.00 . All payouts during the period have been reinvested in the units of the scheme at the then prevailing NAV. Load is not considered for computation of returns. While calculating returns dividend distribution tax is excluded. Scheme in existence for less than 1-year performance details are not provided.
- 7) The last 2 columns represents additional benchmark.
- 8)*Scheme Benchmark , # Additional Benchmark.
- 9) Market capitalization as per SEBI circular : A) Large Cap: 1st -100th company in terms of full market capitalization. B) Mid Cap: 101st - 250th company in terms of full market capitalization. C) Small Cap: 251st company onwards in terms of full market capitalization.

**Mutual Fund Investments are subject to market risks,
read all scheme related documents carefully**



Disclosure for Composite CAGR Calculation

Scheme Name	Index Name	Remarks
Tata Large & Mid Cap Fund - Reg - Growth	Nifty LargeMidcap 250 TRI	As TRI data is not available since Inception of the scheme, benchmark performance is calculated using composite CAGR of Nifty Large & Midcap 250 PRI values from date 25-Feb-1993 to date 31-Mar-2005 and TRI values since date 01-Apr-2005.
Tata Young Citizens Fund - Reg	S&P BSE 200 TRI	As TRI data is not available since Inception of the scheme, benchmark performance is calculated using composite CAGR of S&P BSE 200 PRI values from date 14-Oct-1995 to date 31-Jul-2006 and TRI values since date 01-Aug-2006.

**Mutual Fund Investments are subject to market risks,
read all scheme related documents carefully**

Toll Free Number : **1800-209-0101** | SMS: **TMF to 57575**